Small molecules that reactivate mutant p53.

V J N Bykov, G Selivanova, K G Wiman

Journal: European journal of cancer (Oxford, England : 1990) 2003;39(13):1828-34

PMID: 12932659

Full Text on Elsevier Science View on PubMed

Abstract

Around half of all human tumours carry mutant p53. This allows escape from p53-induced cell cycle arrest and apoptosis. Many tumours express mutant p53 proteins at elevated levels. Restoration of wild-type p53 function should trigger massive apoptosis in tumour cells and thus eradicate tumours. Various types of small molecules have been identified that can restore native conformation and wild-type function to mutant p53. Such molecules may serve as leads for the development of novel efficient anticancer drugs.

Address: Department of Oncology-Pathology, Cancer Center Karolinska, SE-171 76 Stockholm, Sweden.

DOI: 10.1016/s0959-8049(03)00454-4